Q1 2021 13F Holders as of 3/31/2021
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
89.4M
-
Number of holders
-
147
-
Total 13F shares, excl. options
-
62.6M
-
Shares change
-
+10.4M
-
Total reported value, excl. options
-
$1.56B
-
Value change
-
+$255M
-
Put/Call ratio
-
0.75
-
Number of buys
-
92
-
Number of sells
-
-58
-
Price
-
$24.97
Significant Holders of Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TVTX) as of Q1 2021
183 filings reported holding TVTX - Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q1 2021.
Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TVTX) has 147 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 62.6M shares
of 89.4M outstanding shares and own 70% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (5.61M shares), BlackRock Inc. (4.83M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (4.55M shares), JANUS HENDERSON GROUP PLC (4.15M shares), VANGUARD GROUP INC (4M shares), PERCEPTIVE ADVISORS LLC (3.3M shares), MACQUARIE GROUP LTD (2.74M shares), STATE STREET CORP (2.44M shares), BANK OF AMERICA CORP /DE/ (2.44M shares), and ARMISTICE CAPITAL, LLC (2.36M shares).
This table shows the top 147 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.